Table 2.
Summary of results of chimerism quantification by qPCR in relapsed patients. AML: Acute Myeloid Leukemia; MDS: Myelodysplastic Syndrome; RAEB2: Refractory Anemia with Excess Blasts type 2; CLL: Chronic Lymphocytic Leukemia; MF: Myelofibrosis; ALL: Acute Lymphoblastic Leukemia; CC: complete chimerism; MC: mixed chimerism; MM: molecular MRD marker.
| Patient ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Diagnosis | AML | MDS (RAEB2) |
CLL | MF | AML | AML | ALL | AML |
| Relapse (days after HSCT) | 1815 | 90 | 1703 | 253 | 479 | 322 | 218 | 363 |
| Date of prior sample (days before relapse) | 363 | 21 | 72 | 7 | 85 | 112 | 45 | 31 |
| Type of prior sample | PB | PB | PB | PB | PB | PB | PB | BM |
| Result qPCR in prior sample | CC | MC | MC | MC | MC | MC | MC | CC |
| Quantification qPCR in prior sample (% recipient) |
0.017 | 0.2 | 1.5 | 1 | 0.15 | 0.159 | 0.1 | 0.003 |
| MM | WT1 | None | None | None | NPM1 | WT1 | None | WT1 |
| Result MM at relapse | Pos | - | - | - | Pos | Pos | - | Neg |
| Result MM in prior sample | Neg | - | - | - | Neg | Neg | - | Neg |